Investor Presentation - Baader Bank Swiss Equities Conference 13 January 2021 Steven Goh
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Investor Presentation Baader Bank Swiss Equities Conference 13 January 2021 Steven Goh CEO
Important Notice & Disclaimer “Forward Looking Statements” Disclaimer
This presentation has been prepared by the management of the The documents provided contain statements related to our future
‘Company’ in connection with meetings with private and institutional business and financial performance and future events or
investors, and not as specific advice to any particular party or person. developments involving the Company that may constitute forward-
The information is based on publicly available information, internally looking statements. These statements may be identified by words
developed data and other sources. Where any opinion is expressed in such as "expects," "looks forward to," "anticipates," "intends," "plans,"
this presentation, it is based on the assumptions and limitations "believes," "seeks," "estimates," "will," "project" or words of similar
mentioned herein and is an expression of present opinion only. No meaning. We may also make forward-looking statements in other
warranties or representations can be made as to the origin, validity, reports, in presentations, in material delivered to stockholders and in
accuracy, completeness, currency or reliability of the information. The press releases. In addition, Company representatives may from time
Company disclaims and excludes all liability (to the extent permitted to time make oral forward-looking statements. Such statements are
by law) for losses, claims, damages, demands, costs and expenses of based on the current expectations and certain assumptions of the
whatever nature arising in any way out of or in connection with the Company’s management, and are, therefore, subject to certain risks
information, its accuracy, completeness or by reason of reliance by and uncertainties. A variety of factors, many of which are beyond the
any person on any of it. Company’s control, affect the Company’s operations, performance,
business strategy and results and could cause the actual results,
performance or achievements of the Company to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements or
anticipated on the basis of historical trends. Due to rounding,
numbers presented throughout this and other documents may not
add up precisely to the totals provided and percentages may not
precisely reflect the absolute figures. The documents provided in this
presentation include supplemental financial measures that are or
may be non-GAAP financial measures.
Achiko – real COVID-19 solutions
Developing tools that address critical needs in fighting COVID-19
… with broader applications in telehealth infrastructure
GUMNUTS TEMAN SEHAT
Aptamer based diagnostics test (“Health Buddy”)
• Simple supply chain – avoids • Integrated • The COVID-19 testing,
the supply problems from passport and access app
diagnostic, passport • Privacy
reagent shortages
• Successful lab tests and coupon system • Coupon feature supports
completed in Spain • Complements loyalty and encourages
• Clinical validation testing by vaccination participation
independent firms • Being rolled out in two
campaigns Indonesian cities
• Key part of getting • 146,000 users since launch
life back to normal in July
Contents
1 Achiko today
the telehealth platform of tomorrow
2 Global need for multiple COVID-19 solutions
safe, simple, available
3 Gumnuts
revolutionising COVID-19 testing
4 Teman Sehat (Health Buddy)
creating safe places to work and play
5 Business Model
making it work for all stakeholders
Achiko Today
Telehealth
Platform
Of Tomorrow
Achiko Today The telehealth platform of tomorrow Renewed, Significant changes to Focus strategy on reset and management and COVID-19 solutions refocussed Board Rapid progress in Teman Sehat roll-out in developing multiple Indonesian cities; COVID-19 solutions Gumnuts in clinical validation potential broader application trials in telehealth infrastructure
It’s a Pandemic …
Global need for Solutions: Safe, Simple, Available Sustained use of variety of solutions to get back to “normal” “Modalities in the combination prevention “toolbox” against the spread of SARS-CoV-2 include wearing masks, physical distancing, hand hygiene, prompt testing (along with isolation and contact tracing), and limits on crowds and gatherings. If a vaccine has only moderate efficacy, or if vaccine uptake is low, these other modalities will be even more critical.” Anthony S. Fauci , MD et. al Vaccines Behavioural Health passports Multiple solutions Hand hygiene Passports for access emerging Masks & PPE Facilitate business reopening Efficacy Social distancing Encourage frequent testing Acceptance Diagnostics Therapeutics Telehealth Platform Critical for contact tracing Equipment Record test Regular widespread testing Drugs Hold health passports Convenience / non-invasive Infrastructure Speed up contact tracing testing Rapid Assessment Supply Chain
We’re encouraged and excited about
Vaccines, but…
Most of the world won’t be vaccinated It’s slowly mutating... 1st world may be out of trouble by 2022,
in 2021… but LMICs may take longer..
Testing and public assurance systems may remain
important for many years to come....Multiple layers of protection
Swiss Cheese Respiratory Pandemic Defence Model
Gumnuts provides
the testing “But it requires all of those things, not just one of those things. I think
that’s what our population is having trouble getting their head
Teman Sehat around. We want to believe that there is going to come this magic day
supports the tracing when suddenly 300 million doses of vaccine will be available and we
can go back to work and things will return to normal.”
Source: New York Times Dr Julie Gerberding, Exec VP and Chief Patient Officer, MerckGumnuts
Aptamer-based Diagnostic test
A DNA Aptamer is a synthetic strand of DNA. Success in invitro. Currently in clinical validation trials with results in
Q1 2021.
If successful, Gumnuts will be ….
Fast
Sampling is easy – saliva
Rapid point-of-care and point-of-need diagnostics
and can be embedded daily protocols.
Affordable
Reduced sample handling logistics
Costs: < US$1.0 per test.
Allows for regular whole-population testing
Step change in contact tracing effectiveness
Simple
Readily available raw materials
Low risk supply chain
Effective Source: Nature ( https://www.nature.com/articles/d41586-020-02661-2 )
Allows for whole-population testing at regular intervals
Note: The variation in sensitivity according to proximity to the onset of
Creates step change in contact tracing model
COVID-19 symptoms may differ for each type of test.Gumnuts
out of the lab, into the field
A DNA Aptamer is a synthetic strand of DNA
and can be applied in substitution to an
Enzyme as a probe. Offers advantages over
other rapid tests for Cost, Supply, Stability and
Specificity. And as such, can be used in a wider
array of test formats.
Preliminary patent lodged in August
2020 by FB Rice
Successful invitro tests in Barcelona
and University of Rovira, Spain
Clinical validation trials in Europe, Asia
Results expected in early Q1 2021
Proceeding to Product
Development (multiple prototypes
in development), and approvals in
1H 2021Teman Sehat
Ecosystem: creating safe places to work and play
User
Health and
Vaccination Coupon
Passports
Tester User App Places App
App Health passport Passport access
Input results Coupons Tester PlacesTeman Sehat (TS) – Public Assurance Platform
Model pays for testing / vaccination and contributions to public safety
Health Consumers Venues
TS in the Cloud TS in the Cloud
Clinics
Appointments, Coupons, Health
payments and and vaccine
Health passports and QR
passports codes
Apps Tester User Places
Benefits - Test Certificate - Easy way to book and pay for - Ecosystem attracts
becomes valuable. COVID-19 tests customers and
- Safe, simple - Test Becomes Valuable provides a safe
appointment - Cost of the Test may be born by environment
process usage, subsidised by places, or - Cost-efficient
- Seamless payments be paid for by a sale (ie, in advertising (Places
coupons) bring traffic back
- Wallet structure means that through realised
many tests, vaccine certificates, business ie in coupons)
etc can be included
Business - Helping communities - TS earns small fee for - TS generates a fee for
get back to normal each COVID-19 test and each User check-in to a
model
thereby vaccine Place
strengthening social - TS ecosystem builds User - Value of returned traffic
licence engagement and loyalty paid for by realised sales
(ie in coupons)Teman Sehat
… ready for scale and expansion
as a v2.0 in Q1 2021
From July 2020 launch in Pekanbaru
• Now has 164,000 users
• 800 locations
• 12,000 coupons offered
• 1,100 coupons redeemed
• Paying for testing (and ready for
vaccinations)Business Model: Making it Work
GUMNUTS TEMAN SEHAT
• Gumnuts model is local partnership for • Teman Sehat revenue model is check-ins,
approvals and assembly for mass scale and coupon redemptions, testing volumes. It
distribution, control and sale of the IP, and can work with any existing test, however
supply of Active Compound from 2 -3 works best with Gumnuts
controlled locations.
• Revenue drivers: Sale of test kits • Revenue drivers: Registered users and
check-ins to PlacesBoard of
Directors
ALLEN WU STEVEN GOH JOHN LIN CHRIS LAURENT
Chairman of the Board Director/Chief Director Director/ VP of Business
Executive Officer Development
Serial entrepreneur • Serial Entrepreneur: Founded • Development and • Experience in international
• Sectors including media, Australia’s first online stockbroking marketing of gaming business
FinTech and investments company, managed / co-managed across social, online, and • Enterprise sales
across Asia and Africa over 120 IPOs, Cofounded one of the integrated resorts • Strategic and operational
world’s first Social Networks, internationally since 2002 marketing management
• Consulted to Media, tech and finance, • Current COO of • Corporate fundraising
• Advised dozens of incubators and PlayStudios
hundreds of startups,
• Appeared in CNN, WSJ, Bloomberg,
Economist and many others.
Executive
Team (Key
Members)
MORRIS BERRIE CHRISTOPHER YOUNG RÜDIGER PETRIKOWSKI DR. MICHAEL EDEL
President Chief Operations Officer Chief Financial Officer Chief Scientist
• Over 20 years of scientific, • Senior executive in financial services, • Entrepreneurial CFO with M&A • Co-founder and director of
business and financial investment banking and wealth and capital market Regenacellx, specialising in
experience in the biotechnology management • Expertise experienced in large & Regenerative Medicine
and healthcare industries • Over 35 years work experience • Managed mid-sized Enterprises on • Developing a DNA
• Consults and advises the successful delivery of large corporate & operating level aptamer- based technology
government organisations, projects including core banking in response to Covid-19
regions and companies transformations • Served as a visiting
throughout the biotech sector • Certified Project Management academic at Harvard (2000),
on the commercialisation of Professional VCRRI Sydney (2012)
science, including business (PMP), Scrum Master and Agile/DevOps and Oxford University
development and capital raising Coach (2018-2019)The Immediate Future...
• Trial results for Gumnuts in Q1 2021
• Joint Ventures for Sales and
Production
• Expand and Grow Teman Sehat
• RebrandingGlossary Aptamer DNA aptamers are short single-strand DNA molecules that that bind to specific targets with high affinity based on structural configuration Coupon A discount or special offer provided by a Place that gives the User some discounted price or purchase offer. While visible to the User when nearby or when searching for offers, it is only available to be claimed once the User has checked-in at the Place. Cloud based storage of Coupons ensures that Coupon’s are used only the appropriate number of times. Place A retail store, an entertainment or food and beverage venue Tester A hospital or health clinic that undertakes COVID-19 test and has staff that have been trained and verified and are able to load User test results as COVID-19 Certificates via the Tester App User The consumer that requires a COVID-19 test and the customer or visitor to a Place that requires a COVID-19 Passport to Check-in
CORPORATE
DATA
Shareholders >3% (27.5%)
• 12.88% Heracles Investment Group Ltd
• 9.42% PT Media Nusantra Citra Tbk
• 5.18% Neural Networks Limited
Achiko AG Last 30 days
Tessinerplatz 7
8002 Zurich
Switzerland
ACHI:SWX
ISIN: CH0522213468
Email: ir@achiko.com
• 106,130,525 shares
Website: www.achiko.com • 8,664,494 shares (non-redeemable,
convertible notes)
• 13,448,821 optionsYou can also read
